A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Unconjugated belantamab antibody
DRUG: Belantamab mafodotin
DRUG: Unconjugated belantamab antibody and belantamab mafodotin
DRUG: Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin

Sponsor

GlaxoSmithKline